Floatz logo

PANITUMUMAB

Osteoarthritis, Knee

University of Albertamonoclonal_antibodyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Osteoarthritis, Knee cohort.

Asset / SponsorPhaseRating
Naproxen
Pfizer
Phase 3BB
Dfn-15
Pfizer
Phase 4BB
Oxycodone
Riku Antero Palanne
Phase 3BB
Liraglutide
Boston Medical Center
Phase 4BB
HYALURONATE
Beijing Tiantan Hospital
Phase 4BB

View all 32 →

Same molecule, other indications

PANITUMUMAB is also rated in:

neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
malignant pancreatic neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →